Kimberly Clark Supports International Infection Prevention Week Oct. 17-23
Infection Prevention, Give Healing a Hand
Need to VENT about "Ventilator-Associated Pneumonia"?
Reach Out, Connect and Engage with Peers... Anytime, Anywhere
We've created our own Kimberly-Clark* KimVent* VAP Solutions website, www.VAP.KChealthcare.com and social media networks where you can Connect and Engage with other like-minded clinicians through social media.
Blog about VAP Prevention "Best Practices" success stories
Search for and share product and procedure video demonstrations
Engage in on-going debates about the latest regulatory issues impacting your practice
Posting questions about clinically- accredited education courses
VAP? Not On My Watch.
After
working with critical care clinicians for more than 25 years in their fight
against Ventilator-Associated Pneumonia, Kimberly-Clark* is committed
to helping you keep VAP off your watch by bringing together our entire
range of VAP solutions under one family.
KIMVENT* VAP Solutions include a wide range of products, accredited clinical education, in-service training and compliance programs all designed to help you provide consistent and comprehensive care for your patients, "Best Practices" critical to protecting them from VAP. Let us prove it.
From the leader in closed suctioning, Kimberly-Clark* KimVent Closed Suction Systems feature advanced infection control benefits that have redefined the standard of care by reducing the risk of cross-contamination and helping you protect your patients from VAP.
See the Proof. Please click here to open the attached Closed Suction Microbiology Report (pdf)
Kimberly-Clark* KimVent* Microcuff* Endotracheal Tubes feature revolutionary cuff technology that achieves superior protection against micro-aspiration, enabling clinicians to provide their patients the best protection from VAP.
Featuring an advanced micro-thin polyurethane cuff designed to provide a superior tracheal seal, KimVent* MICROCUFF* Endotracheal Tubes provide superior protection. But don't take our word for it, Prove It To Yourself. Watch the video.
Proven to Enable a More Accurate Diagnosis for more effective and targeted antibiotic treatment
KimVent* BAL-Cath* Sampling Catheters enables safe and quick retrieval of a patient's lower respiratory tract secretions.
By providing the accurate sample needed to make an accurate lung infection diagnosis, physicians are equipped to prescribe targeted antibiotic treatment, critical to reducing antibiotic usage and costs.
With the power of targeted treatment, KimVent* BAL Cath* Catheter can help you protect your patients from VAP.
Proven to Enhance Oral Care Compliance....CHG Comming Soon!
Because oral care is critical to preventing VAP, we offer KimVent* Oral Care Solutions, a complete line of flexible, easy-to-use Oral Care q4, q2 Kits and Components.With our Partners In Prevention Oral Care Compliance Program, we work closely with your team in providing evidence-based "Best Practices", tools, resources and support designed to help you deliver comprehensive and consistent oral care.
Watch our video to meet Barbara, an ICU nurse, as she shares the advantages of Kimberly-Clark's KimVent* Oral Care Solutions, a portfolio of easy-to-use kits and components that can help you meet your oral care protocols.
See the Proof.
Nine out of 10 clinicians agree that KIMBERLY-CLARK* KIMVENT* ORAL CARE Q4 Kit is easier to use, easier to comply with protocols and encourages oral care frequency.
Kim-Vent* Product Evaluation (q4) Final Research Results
A
subset of HAP, Ventilator-Associated Pneumonia (VAP) refers to those
cases that occur in patients who have been on ventilator support for
at least 48 hours. The mechanisms for HAP and VAP infections are
similar, although due to the fact that host defenses against pneumonia
are so effectively bypassed by an endotracheal tube, the risk of
pneumonia in ventilated patients is much higher.
Early-onset
VAP is defined as hospital-acquired pneumonia that develops in patients
who have been on a ventilator between 48 and 96 hours or less than four
days. These patients may have had emergent, traumatic intubations or
major chest, abdominal or neurosurgery. The usual pathogens associated
with early onset VAP are most commonly the patient’s own normal,
antibiotic-sensitive flora, such as methicillinsensitive Staphylococcus
aureus (MSSA), Haemophilus influenza or Streptococcus pneumoniae.
Late-onset
VAP is defined as hospital-acquired pneumonia that develops in patients
who have been on a ventilator five days or longer. These patients often
present with many pre-existing chronic conditions that predispose them
to lung infections, such as chronic obstructive pulmonary disease
(COPD) or cardiac-related pulmonary edema. The pathogens most commonly
seen with late-onset VAP are the more resistant strains of bacteria
such as methicillin-resistant Staphylococcus aureus (MRSA) or
gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter,
Enterobacter, Klebsiella or Serratia.
Ventilated
patients are especially susceptible to pneumonia as their normal host
defenses are hampered, blocked or disabled during mechanical
ventilation by the physical presence of the assisted-breathing device.
The bacteria and other microorganisms, which are normally blocked or
carried away from the respiratory tract, have the ability to bypass the
normal body defenses and enter the lungs. In order to understand the
vulnerabilities of the ventilated patient, a review of the normal
reflexes and clearance mechanisms is helpful.
Approximately 8-28% of critical care patients develop VAP
Healthcare-associated pneumonia patients have a mortality rate of 20% to 33%
VAP increases patient time in the ICU by 4 to 6 days
Each incidence of VAP is estimated to generate an increased cost of $20,000 to $40,0001
VAP accounts for 47% of all infections in ICU.
Mortality rates for VAP are between 20% and 70%.
VAP leads to increased hospitalization stays, costs, and mortality.
Ventilator-associated
pneumonia (VAP) is one of the most common health care-associated
infections (HAIs) in critical care settings.
Ventilator-associated pneumonia is defined as pneumonia occurring more than 48 hours after patients have been intubated and received mechanical ventilation.
Prevention of VAP involves limiting exposure to resistant bacteria, discontinuing mechanical ventilation as soon as possible, and a variety of strategies to limit infection while intubated.
Proper hand washing, sterile technique for invasive procedures, and isolation of individuals with known resistant organisms are all mandatory for effective Ventilator Associated Pneumonia control.
To learn more about the impact of healthcare-associated infections for both medical professionals and patients, please visit haiwatch.com/VAP.
Handwashing The
practice of handwashing and the wearing of gowns and gloves are basic
and quite possibly the most important actions taken for reducing
colonization. Methicillin Resistant Staphylococcus aureus (MRSA) is
commonly spread by caregivers’ hands.12 Gloves and gowns have been
shown to be effective in preventing the nosocomial spread of antibiotic
resistant bacteria including Vancomycin-resistant enterococci (VRE) as
well as MRSA.
Oral Hygiene The
importance of patient oral and nasal hygiene is often overlooked,
although it is one of the most basic of nursing interventions. Sole
found that less than half of the 27 surveyed sites (48%) had written
policies for oral care of intubated patients, and even fewer (37%) had
oral suction policies.22 The use of closed suction systems (CSS) may
contribute to the inattention paid to oral care in that oral suctioning
is an integral part of traditional open suction procedures. Yet, it is
widely recognized that the mouth is a virtual garden of normal
bacterial flora and pathogenic organisms. Both Kollef7 and Kunis12 have
advocated chlorhexidine oral rinse to reduce the oral bacterial load;
however, its regular use may lead to chlorhexidine resistant organisms.
Several studies have shown that oral decontamination is an effective
method for reducing VAP.
VAP Risk Factors The
single largest VAP risk factor is the endotracheal tube. Because
mechanical ventilator support cannot be performed without the
endotracheal tube (or other artificial airway), it is a necessary evil.
The endotracheal tube provides a direct passageway into the lungs,
bypassing many "natural protection" mechanisms. The endotracheal tube
increases the risk for VAP by:
preventing cough (the patients natural defense)
preventing upper airway filtering
preventing upper airway humidification
inhibiting epiglottic and upper airway reflexes
inhibiting cilliary transport by the epithelium
acting as a direct conduit into the lungs for airborne pathogens
potentially acting as a reservoir for pathogens by providing a place for biofilm to form
having a cuff which provides a place for secretions to “pool” in the hypoglottic area
initiating a foreign body reaction, interfering with the local immune response
Other device treatment and personnel related risk factors include:
nasogastric tube placement
bolus enteral feeding
gastric over-distension
stress ulcer treatment
supine patient position
nasal intubation route
instillation of normal saline
understaffing
nonconformance to handwashing protocol
indiscriminate use of antibiotics
lack of training in VAP prevention
At Kimberly-Clark Health Care,
we deliver innovative healthcare solutions that you can depend on to
meet the demands of your fast-paced world, supported by in-service
training, clinical research and accredited education.
Our solutions help you prevent, diagnose, and manage major issues in these clinical areas: Infection Prevention
(Protection & Infection Control, Ventilator-Associated Pneumonia
and Surgical Site Infections), Digestive Health and Pain Management.
Kimberly-Clark and its well-known global brands are an indispensable part of life for people in more than 150 countries.
Every day, 1.3 billion people - nearly a quarter of the world's
population - trust K-C brands and the solutions they provide to enhance
their health, hygiene and well-being.
With brands such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and
Depend, Kimberly-Clark holds No. 1 or No. 2 share positions in more
than 80 countries. To keep up with the latest K-C news and to learn
more about the company's 137-year history of innovation, visit www.kimberly-clark.com
Healthcare-Associated Infection (HAI) Not on My Watch
Embed Code:
HAI Education Bus Not on My Watch
Embed Code:
Handwashing Video HAI Heathcare Associated Infection Prevention